Understanding 1,25(OH)2D3's role in controlling osteoclastic bone resorption will aid in developing clinical approaches to osteoporosis. This proposal will study 1,25(OH)2D3's modulation of two genes critical to osteoclast differentiation and function. We have previously shown that 1,25(OH)2D3 decreases expression of the macrophage colony stimulating factor receptor (MCSFR) while increasing expression of osteoclast characteristics in the HL-60 cell, which serves as a model for the early osteoclast precursor. We postulate that 1,25(OH)2D3's potentiation of osteoclast differentiation involves downregulating the ability of the precursor cell to respond to MCSF: precursor cells with decreased MCSFR would have an increased probability of entering the osteoclast pathway and a decreased probability of MCSF induced entry into the macrophage pathway. We will first show that 1,25(OH)2D3 decreases the expression of MCSFR in marrow cells as they enter the osteoclast pathway by measuring (125)I-MCSF binding and in situ hybridization of MCSFR mRNA in individual osteoclasts and monocytes in culture. The molecular mechanism by which 1,25(OH)2D3 decreases expression of the MCSFR gene will be defined by nuclear run on and study of MCSFR transcript elongation in HL-60 cells. 1,25(OH)2D3 regulation of osteoclast function will be investigated in the second specific aim: the applicant has previously shown in HL-60 cells that 1,25(OH)2D3 and protein kinase C synergistically increase the expression of carbonic anhydrase Il. Regulation of CA II may be a critical means of controlling bone resorption as it is an enzyme necessary for osteoclast function. We propose to study the ability of 1,25(OH)2D3 and PKC to regulate CA Il in mature cultured osteoclasts using reverse transcription polymerase chain reactions to quantify changes in CA Il mRNA. Finally, the interaction of 1,25(OH)2D3 and PKC to enhance CA Il gene transcription will be studied in the HL-60 cell line by nuclear run on. These studies should help eluciate the mechanisms of 1,25(OH)2D3 action in osteoclasts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08AR001945-03
Application #
2330575
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1995-01-16
Project End
2000-01-15
Budget Start
1997-01-16
Budget End
1998-01-15
Support Year
3
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Emory University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322